Intellia Therapeutics (NASDAQ:NTLA) Now Covered by HC Wainwright

HC Wainwright initiated coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 203.03% from the stock’s previous close. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.43) EPS and Q4 2026 earnings at ($1.17) EPS.

NTLA has been the topic of several other reports. William Blair reiterated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Citigroup boosted their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Barclays cut their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, BMO Capital Markets reduced their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $9.90 on Wednesday. Intellia Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $32.00. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1.82 and a beta of 1.97. The stock’s fifty day moving average is $10.64 and its two-hundred day moving average is $15.28.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 29,000 shares of company stock valued at $352,551. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp raised its stake in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of Intellia Therapeutics by 125.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock worth $1,411,000 after purchasing an additional 67,276 shares during the period. Patient Square Capital LP bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $2,642,000. Charles Schwab Investment Management Inc. boosted its position in Intellia Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after purchasing an additional 37,714 shares during the period. Finally, Avanza Fonder AB bought a new position in Intellia Therapeutics during the 4th quarter worth $421,000. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.